Concurrent CD8+ T cell ablation markedly diminished the tumor regression and survival benefits of P-BS-CM1 → P-PS-CM2 (+), validating generation of a localized immune response against the primary tumor (Fig. 8f and Supplementary Fig. 22). The gene discussed is CD8A; the disease is neoplasm.